Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer.

Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL.

J Urol. 2019 Jun 19:101097JU0000000000000393. doi: 10.1097/JU.0000000000000393. [Epub ahead of print]

PMID:
31216253
2.

Conceptual Framework for Therapeutic Development Beyond Anti-PD-1/PD-L1 in Urothelial Cancer.

Grivas P, Drakaki A, Friedlander TW, Sonpavde G.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:284-300. doi: 10.1200/EDBK_237449. Epub 2019 May 17.

PMID:
31099684
3.

Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study.

Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R.

Clin Genitourin Cancer. 2019 Feb;17(1):e92-e96. doi: 10.1016/j.clgc.2018.09.013. Epub 2018 Sep 24.

PMID:
30327180
4.

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Wei XX, Siegel AP, Aggarwal R, Lin AM, Friedlander TW, Fong L, Kim W, Louttit M, Chang E, Zhang L, Ryan CJ.

Oncologist. 2018 Jun;23(6):656-e64. doi: 10.1634/theoncologist.2017-0624. Epub 2018 Feb 27.

5.

Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond.

Zhu J, Armstrong AJ, Friedlander TW, Kim W, Pal SK, George DJ, Zhang T.

J Immunother Cancer. 2018 Jan 25;6(1):4. doi: 10.1186/s40425-018-0314-1. Review.

6.

Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors.

Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP.

PLoS One. 2017 Nov 15;12(11):e0187975. doi: 10.1371/journal.pone.0187975. eCollection 2017.

7.

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.

Powles T, O'Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ, Lee JL, Ong M, Sridhar SS, Vogelzang NJ, Fishman MN, Zhang J, Srinivas S, Parikh J, Antal J, Jin X, Gupta AK, Ben Y, Hahn NM.

JAMA Oncol. 2017 Sep 14;3(9):e172411. doi: 10.1001/jamaoncol.2017.2411. Epub 2017 Sep 14.

8.

High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer.

Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ.

Clin Genitourin Cancer. 2017 Dec;15(6):733-741.e1. doi: 10.1016/j.clgc.2017.05.026. Epub 2017 Jun 3.

PMID:
28655452
9.

Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.

Friedlander TW, Pritchard CC, Beltran H.

Am Soc Clin Oncol Educ Book. 2017;37:358-369. doi: 10.14694/EDBK_175510. Review.

10.

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer.

Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L.

Cancer Immunol Res. 2016 Nov;4(11):948-958. Epub 2016 Sep 29.

11.

An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer.

Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL.

Cancer Lett. 2016 Sep 28;380(1):144-52. doi: 10.1016/j.canlet.2016.06.017. Epub 2016 Jun 22.

PMID:
27343980
12.

Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.

Anantharaman A, Friedlander TW.

Urol Oncol. 2016 Aug;34(8):356-67. doi: 10.1016/j.urolonc.2015.11.003. Epub 2015 Dec 17. Review.

PMID:
26706121
13.

A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate Cancer.

Anantharaman A, Friedlander TW.

Eur Urol. 2015 Dec;68(6):946-8. doi: 10.1016/j.eururo.2015.07.053. Epub 2015 Aug 13. No abstract available.

PMID:
26278804
14.

The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks.

Anantharaman A, Friedlander TW.

Oncology (Williston Park). 2015 Jan;29(1):67-8. No abstract available.

15.

Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens.

Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ.

Clin Cancer Res. 2014 Dec 15;20(24):6269-76. doi: 10.1158/1078-0432.CCR-14-1595. Epub 2014 Oct 21.

16.

The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.

Friedlander TW, Fong L.

J Clin Oncol. 2014 Apr 10;32(11):1104-6. doi: 10.1200/JCO.2013.54.7307. Epub 2014 Mar 10. No abstract available. Erratum in: J Clin Oncol. 2014 Jun 10;32(17):1863.

PMID:
24616311
17.

Looking back, to the future of circulating tumor cells.

Friedlander TW, Premasekharan G, Paris PL.

Pharmacol Ther. 2014 Jun;142(3):271-80. doi: 10.1016/j.pharmthera.2013.12.011. Epub 2013 Dec 19. Review.

PMID:
24362084
18.

Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer.

Friedlander TW, Ngo VT, Dong H, Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ, Chen WT, Paris PL.

Int J Cancer. 2014 May 15;134(10):2284-93. doi: 10.1002/ijc.28561. Epub 2014 Jan 2.

19.

Targeting the androgen receptor.

Friedlander TW, Ryan CJ.

Urol Clin North Am. 2012 Nov;39(4):453-64. doi: 10.1016/j.ucl.2012.07.003. Review.

PMID:
23084523
20.

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer.

Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL.

Cancer Res. 2012 Feb 1;72(3):616-25. doi: 10.1158/0008-5472.CAN-11-2079. Epub 2011 Dec 7.

21.

A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer.

Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Oncol Rep. 2012 Jan;27(1):3-9. doi: 10.3892/or.2011.1487. Epub 2011 Oct 4.

PMID:
21971890
22.

Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.

Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.

Urol Oncol. 2012 Jul-Aug;30(4):408-14. doi: 10.1016/j.urolonc.2010.06.014. Epub 2010 Oct 2.

PMID:
20884247
23.

Editorial comment.

Friedlander TW, Ryan CJ.

J Urol. 2010 Nov;184(5):1976. doi: 10.1016/j.juro.2010.06.161. No abstract available.

PMID:
20884031
24.

Novel hormonal approaches in prostate cancer.

Friedlander TW, Ryan CJ.

Curr Oncol Rep. 2009 May;11(3):227-34. Review.

PMID:
19336015

Supplemental Content

Loading ...
Support Center